Why Organovo Holdings Inc. Shares Tumbled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Organovo Holdings (NYSEMKT: ONVO  ) , a clinical-stage biologics company focused on engineering human tissues that can be used in the drug discovery process or as therapeutic implants, dipped as much as 14% after reporting its full-year results before the opening bell.

So what: According to Organovo's press release, revenue (as much as it has any, given that it's wholly clinical) dipped 67% to $0.4 million from $1.2 million in the prior-year period as operating expenses doubled to $21 million from $10.5 million. Specifically, research and development expenses soared 135% to $8 million, while selling, general and administrative expenses spiked 83% to $13 million. The company announced that it ended the year with $47.3 million in working capital, though the company raised $43.4 million in net proceeds from offering 10.35 million shares during the course of the year.

Now what: While investors are clearly excited about the coming debut of Organovo's first product, a 3-D liver assay test, today's earnings report is a stark reminder that clinical-stage companies burn through cash at an exceptional rate, and if Organovo isn't able to successfully translate its ideas on paper into tangible revenue quickly then it could be forced to seek additional financing. Chances are if you've already come this far with Organovo you're not going to be deterred by its full-year report and are invested for the long haul based on its unique technology. As for me, with an accumulated deficit now topping $92 million I'd much rather stick to the sidelines and let its initial product do all the talking.

Organovo may offer plenty of potential, but keeping up with the growth potential of this top stock may prove impossible
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It’s a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.


Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2992453, ~/Articles/ArticleHandler.aspx, 11/22/2014 4:24:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 17,810.06 91.06 0.51%
S&P 500 2,063.50 10.75 0.52%
NASD 4,712.97 11.10 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2014 4:01 PM
ONVO $6.31 Down -0.26 -3.96%
ORGANOVO HOLDINGS CAPS Rating: ***

Advertisement